Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) is a life sciences technology company that regularly issues news and updates related to its automated microbial quality control (MQC) solutions for pharmaceutical and biopharmaceutical manufacturing. Company press releases focus on the performance and adoption of its flagship Growth Direct system, which automates and modernizes manual MQC testing workflows used in large and complex pharmaceutical manufacturing operations across the globe.
News for RPID often covers quarterly and annual financial results, including product revenue, service revenue, and recurring revenue from consumables and annual service contracts. The company highlights metrics such as system placements, customer system validations, recurring revenue growth, and record consumable revenue. Updates have also described record multi-system orders from an existing Top 20 global biopharma customer to automate a global manufacturing network across North America, Europe, and Asia Pacific.
Investors and industry followers can also expect announcements about capital structure and financing, such as the disclosed five-year, $45 million term loan facility with Trinity Capital Inc., as well as news on the company’s financial position and outlook. Additional news items include participation in major healthcare and investor conferences, including the J.P. Morgan Healthcare Conference, the Stifel Healthcare Conference, and the H.C. Wainwright Global Investment Conference, where management presents and engages with analysts and investors.
This RPID news page on Stock Titan aggregates these types of updates so readers can quickly review earnings announcements, financing developments, system placement milestones, and conference participation related to Rapid Micro Biosystems. Users interested in the evolution of automated microbial quality control in biopharma manufacturing can monitor this feed for the company’s latest publicly released information.
Rapid Micro Biosystems (Nasdaq: RPID) will participate in the Stifel 2025 Healthcare Conference in New York. Management is scheduled for a 30-minute question-and-answer session with the host analyst on Tuesday, November 11, 2025 at 11:20 a.m. ET. A live webcast will be available on the company investor relations website and the webcast will be archived for replay after the event.
Rapid Micro Biosystems (Nasdaq: RPID) will release third quarter 2025 financial results before market open on Friday, November 7, 2025.
The company's management will host a webcast conference call at 8:30 a.m. ET on November 7, 2025 to discuss results; the live audio webcast is accessible on the company website and will be archived for replay.
Trinity Capital (NASDAQ:TRIN) has committed $45 million in growth capital to Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for microbial quality control in healthcare product manufacturing. The funding will support Rapid Micro's global expansion of their Growth Direct® platform and investments in manufacturing efficiency improvements.
The Growth Direct® platform enhances microbial testing processes by providing faster results, improved accuracy, increased operational efficiency, and enhanced data integrity. The capital will be used to scale operations, support commercial expansion, and drive gross margin growth through cost reduction and improved manufacturing efficiency.
Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for Tuesday, September 9, 2025, at 11:00 a.m. ET in New York. Investors can access the live webcast through the company's investor relations website at investors.rapidmicrobio.com, with a replay available after the event.
Rapid Micro Biosystems (NASDAQ:RPID) reported Q2 2025 financial results, with total revenue reaching $7.3 million, up 10% year-over-year. The company demonstrated strong performance with recurring revenue growing 15% to $4.4 million and service revenue increasing 18% to $2.5 million.
The company secured a significant $45 million term loan facility with Trinity Capital, with $20 million funded at closing. Despite a net loss of $11.9 million, RPID showed improvement in gross margin, reaching positive 4% compared to negative 3% in Q2 2024. The company placed four new Growth Direct systems and completed two system validations during the quarter.
RPID reaffirmed its full-year 2025 revenue guidance of at least $32.0 million. The company ended Q2 with approximately $32 million in cash, cash equivalents, short-term investments, and restricted cash.
Rapid Micro Biosystems (NASDAQ:RPID) has secured a $45 million term loan facility with Trinity Capital Inc. The five-year facility includes an initial $20 million drawn at closing, with potential access to an additional $25 million in subsequent tranches.
The loan features an initial 11.5% annual floating interest rate with a 36-month interest-only period, extendable based on future tranche drawdowns. The funding will support the company's Growth Direct system commercial expansion, manufacturing efficiencies, and product cost reduction initiatives, aiming to strengthen its path toward positive cash flow.
Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, has scheduled its Q2 2025 financial results announcement for August 12, 2025.
The company will release results before market open, followed by a management-hosted webcast conference call at 8:30 a.m. ET on the same day. The webcast will be available on the company's website and archived for future reference.
Rapid Micro Biosystems (NASDAQ: RPID) reported strong Q1 2025 financial results with total revenue of $7.2 million, representing a 28% growth year-over-year. The company achieved record quarterly service revenue of $3.1 million, up 64% from Q1 2024. Product revenue increased 10% to $4.1 million, while recurring revenue grew 6% to $4.0 million.
Notable achievements include placing three new Growth Direct® systems and completing nine customer system validations. Gross margin improved significantly to positive 6% from negative 27% in Q1 2024. Operating expenses decreased 5% to $12.1 million, and net loss improved to $11.3 million ($0.26 per share) from $13.3 million ($0.31 per share) year-over-year.
The company announced a global Distribution and Collaboration Agreement with MilliporeSigma and reaffirmed its 2025 revenue guidance of at least $32.0 million, targeting 21-25 system placements.